Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...
Wisetack Partners With U.S. Bank to Expand Embedded Pay-Over-Time Financing Options in Home Services
The latest partnership with U.S. Bank is part of Wisetack's innovative embedded origination program, which has reshaped the bank-fintech relationship model by enabling banks to serve both borrowers ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has ...
Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and ...
We bought a home six years ago, and my husband has refused to pay any money toward the mortgage this whole time. He forced me to pay every payment. We live in California. Is he entitled to half of ...
Apple discontinued its Apple Pay Later service this summer, but several third-party options have been added since, including Synchrony today.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback